摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(4-溴苯基磺酰基)哌嗪 | 179334-20-4

中文名称
1-(4-溴苯基磺酰基)哌嗪
中文别名
——
英文名称
1-((4-bromophenyl)sulfonyl)piperazine
英文别名
1-(4-bromophenylsulphonyl)piperazine;1-(4-bromophenyl)sulfonylpiperazine
1-(4-溴苯基磺酰基)哌嗪化学式
CAS
179334-20-4
化学式
C10H13BrN2O2S
mdl
MFCD00474647
分子量
305.195
InChiKey
JIABXBYOURNKRZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    417.3±55.0 °C(Predicted)
  • 密度:
    1.549±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.1
  • 重原子数:
    16
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.4
  • 拓扑面积:
    57.8
  • 氢给体数:
    1
  • 氢受体数:
    4

安全信息

  • 危险品标志:
    Xi
  • 海关编码:
    2935009090

SDS

SDS:3cb55a08bd918bf94658dbc01ea59a9f
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 1-(4-Bromophenylsulfonyl)piperazine
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 1-(4-Bromophenylsulfonyl)piperazine
CAS number: 179334-20-4

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C10H13BrN2O2S
Molecular weight: 305.2

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide, sulfur oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    1-(4-溴苯基磺酰基)哌嗪正丁基锂硼酸三异丙酯 作用下, 以 四氢呋喃 为溶剂, 反应 18.0h, 以40%的产率得到B-[4-(1-Piperazinylsulfonyl)phenyl]boronic acid
    参考文献:
    名称:
    使用虚拟筛选和初步的,结构指导的铅作用域发现具有新型结合模式的强力CDK2抑制剂。
    摘要:
    针对pCDK2 / cyclin A的晶体结构的虚拟筛选导致鉴定出了有效的新型CDK2抑制剂,该抑制剂表现出与激酶结合基序相互作用的异常模式。借助X射线晶体学和建模,实施了一种药物化学策略,以探查晶体结构中的相互作用并建立SAR。还考虑了基于片段的方法,但是观察到了不同的,更常规的结合模式。使用合理的设计策略,通过对CDK2结合模式的晶体学验证,提高了对GSK-3beta的化合物选择性。
    DOI:
    10.1016/j.bmcl.2007.04.110
  • 作为产物:
    描述:
    4-溴苯磺酰氯盐酸溶剂黄146三乙胺 作用下, 以 二氯甲烷 为溶剂, 反应 50.0h, 生成 1-(4-溴苯基磺酰基)哌嗪
    参考文献:
    名称:
    Novel Benzo[b]thiophene Derivatives as New Potential Antidepressants with Rapid Onset of Action
    摘要:
    We report benzo[b]thiophene derivatives synthesized according 10 a dual strategy. 8j, 9c, and 9e with affinity values toward 5-HT(7)R and 5-HTT were selected to probe their antidepressant activity in vivo using the forced swimming text (FST). The results slowed significant antidepressant activity after chronic treatment. 9c was effective in reducing the immobility time in FST even after acute treatment. These findings identify these compounds as a new class of antidepressants with a rapid onset of action.
    DOI:
    10.1021/jm2000773
点击查看最新优质反应信息

文献信息

  • Sulfonylpiperazines based on a flavone as antioxidant and cytotoxic agents
    作者:Rahul V. Patel、Bhupendra M. Mistry、Riyaz Syed、Nikhil M. Parekh、Han‐Seung Shin
    DOI:10.1002/ardp.201900051
    日期:2019.9
    Chrysin‐based sulfonylpiperazines 7a‐k were synthesized and investigated for their in vitro free radical scavenging potential as well as cytotoxic efficacies against selected cancer cell lines. Cytotoxicity of the new compounds toward noncancer cells was confirmed using the SRB assay against Madin–Darby Canine Kidney cells. Reaction of piperazine with different substituted benzenesulfonyl chlorides
    合成了基于白杨素的磺酰基哌嗪 7a-k,并研究了它们的体外自由基清除能力以及对选定癌细胞系的细胞毒性作用。使用针对 Madin-Darby 犬肾细胞的 SRB 测定证实了新化合物对非癌细胞的细胞毒性。哌嗪与不同取代苯磺酰氯在三乙胺提供的磺酰哌嗪 (3a-k) 中反应,然后与 7-(4-溴丁氧基)-5-羟基-2-苯基-4H-色胺-4-酮 (6 ) 制备白杨素与 1,4-二溴丁烷反应得到最终衍生物 7a-k。结果表明,白杨素-磺酰基哌嗪比以前研究的白杨素-哌嗪前体具有更好的抗氧化和抗癌功效。例如,化合物 7h、7j 和 7k 与 4-OCF3、4-OCH3、和 2,4-diOCH3 基团对 2,2-diphenyl-1-picrylhydrazyl (DPPH) 和 2,2'-azino-bis-3-ethylbenzothiazoline-6-sulfonic acid (ABTS) 自由基
  • New Pyridinones and Isoquinolinones as Inhibitors of the Bromodomain BRD9
    申请人:Boehringer Ingelheim International GmbH
    公开号:US20180044335A1
    公开(公告)日:2018-02-15
    The present invention encompasses compounds of general formula (I) wherein the groups R 1 to R 9 , X 1 and X 2 have the meanings given in the claims and in the specification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, e.g. cancer, pharmaceutical preparations containing such compounds and their uses as a medicament.
    本发明涵盖了一般式(I)的化合物,其中基团R1至R9,X1和X2的含义如权利要求和说明书中所述。本发明的化合物适用于治疗由细胞过度或异常增殖所特征化的疾病,例如癌症,含有这种化合物的制药制剂以及它们作为药物的用途。
  • Design and synthesis of substituted (1-(benzyl)-1<i>H</i>-1,2,3-triazol-4-yl)(piperazin-1-yl)methanone conjugates: study on their apoptosis inducing ability and tubulin polymerization inhibition
    作者:Kesari Lakshmi Manasa、Sowjanya Thatikonda、Dilep Kumar Sigalapalli、Sowmya Vuppaladadium、Ganthala Parimala Devi、Chandraiah Godugu、Mallika Alvala、Narayana Nagesh、Bathini Nagendra Babu
    DOI:10.1039/d0md00162g
    日期:——
    cytotoxicity with the IC50 value of 0.99 ± 0.01 μM towards BT-474 cancer cell line. The target compound (10ec) was also evaluated for its tubulin polymerization inhibition study. Detailed biological studies such as acridine orange/ethidium bromide (AO/EB), DAPI and annexin V-FITC/propidium iodide staining assay suggested that compound 10ec induced the apoptosis of BT-474 cells. The clonogenic assay revealed that
    设计、合成和筛选了取代的(1-(苄基)-1 H -1,2,3-三唑-4-基)(哌嗪-1-基)甲酮衍生物文库,并筛选了它们对 BT- 的体外细胞毒活性474、HeLa、MCF-7、NCI-H460 和 HaCaT 细胞,采用 3-(4,5-二甲基噻唑-2-基)-2,5-二苯基溴化四唑 (MTT) 测定。在所有合成的类似物中,化合物10ec对 BT-474 癌细胞系显示出最高的细胞毒性,IC 50值为 0.99 ± 0.01 μM。目标化合物 ( 10ec) 还对其微管蛋白聚合抑制研究进行了评估。详细的生物学研究如吖啶橙/溴化乙锭 (AO/EB)、DAPI 和膜联蛋白 V-FITC/碘化丙啶染色试验表明,化合物10ec诱导了 BT-474 细胞的凋亡。克隆形成试验显示 BT-474 细胞中的集落形成被10ec以浓度依赖性方式抑制。此外,流式细胞术分析显示,10ec通过在亚 G1 和 G2/M
  • Heterocyclic compounds useful as oxido-squalene cyclase inhibitors
    申请人:Zeneca Limited
    公开号:US06391880B1
    公开(公告)日:2002-05-21
    This invention concerns heterocyclic derivatives of formula (I) which are useful in inhibiting oxido-squalene cyclase, processes for their preparation and pharmaceutical compositions containing them. The present invention is also concerned with heterocyclic derivatives capable of inhibiting cholesterol biosynthesis and hence in lowering cholesterol levels in blood plasma. The present invention also relates to methods of using such heterocyclic derivatives in diseases and medical conditions such as hypercholesterolemia and atherosclerosis.
    这项发明涉及式(I)的杂环衍生物,其在抑制氧化齿萜环化酶方面具有用途,以及其制备方法和含有它们的药物组合物。本发明还涉及能够抑制胆固醇生物合成并因此降低血浆胆固醇水平的杂环衍生物。本发明还涉及在高胆固醇血症和动脉粥样硬化等疾病和医疗状况中使用这种杂环衍生物的方法。
  • Substituted pyrimidine derivatives and their pharmaceutical use
    申请人:Zeneca Limited
    公开号:US06093718A1
    公开(公告)日:2000-07-25
    This invention concerns heterocyclic derivatives which are useful in inhibiting oxido-squalene cyclase, processes for their preparation and pharmaceutical compositions containing them. The present invention is also concerned with heterocyclic derivatives capable of inhibiting cholesterol biosynthesis and hence in lowering cholesterol levels in blood plasma. The present invention also relates to methods of using such heterocyclic derivatives in diseases and medical conditions such as hypercholesterolemia and atherosclerosis.
    这项发明涉及对氧化齿萜环化酶具有抑制作用的杂环衍生物,以及其制备方法和含有它们的药物组合物。本发明还涉及对能够抑制胆固醇生物合成并因此降低血浆胆固醇水平的杂环衍生物。本发明还涉及在高胆固醇血症和动脉粥样硬化等疾病和医疗状况中使用这种杂环衍生物的方法。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐